Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases
Emmanuella Amoako abc, Setor Amuzu a, Emmanuel Owusu Ofori b, Harry Sefoga Akligoh a, Randy Tackie a, Barikisu Anna Ibrahim a, Emmanuel Kofi Quaye a, Patrick Kafui Akakpo bcd, Luke Adagrah Aniakwo b, Bashiro Jimah bc, Kofi Ulzen-Appiah bc, David Hutchful a, Aida Manu a, Joyce M Ngoi a, Lily Paemka a, Yakubu Alhassan ae, Ernest Amo Obeng d, Nicole Lim f, Lisa Rajah f, Michelle Pek f…Yaw Bediako a Transl Oncol; 49: 102100, 2024 Nov, https://doi.org/10.1016/j.tranon.2024.102100 Abstract Purpose: Breast cancer is a major cause of cancer-related mortality among African women. The adoption of molecular genomic technologies in the management of cancer cases is limited in Africa. To provide much-needed insights on the feasibility and utility […]
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.